Evidence map›Paper›PMID 28005930›Full record

ArticlePloS one2016

Nanoparticle Tracking Analysis for the Enumeration and Characterization of Mineralo-Organic Nanoparticles in Feline Urine.

M Mellema, M Stoller, Y Queau, S P Ho, T Chi, J A Larsen, N Passlack, A J Fascetti, C Mohr, J L Westropp

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

M MellemaDepartment of Veterinary Surgical and Radiological Science, School of Veterinary Medicine, University of California Davis, Davis, California, United States of America.
M StollerDepartment of Urology, School of Medicine, University of California San Francisco, San Francisco, California, United States of America.
Y QueauRoyal Canin Research & Development Center, Aimargues, France.
S P HoDepartment of Preventive and Restorative Dental Sciences, School of Dentistry, University of California San Francisco, San Francisco, California, United States of America.
T ChiDepartment of Urology, School of Medicine, University of California San Francisco, San Francisco, California, United States of America.
J A LarsenDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, California, United States of America.
N PasslackInstitute of Animal Nutrition, Department of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
A J FascettiDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, California, United States of America.
C MohrDepartment of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, United States of America.
J L WestroppDepartment of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California Davis, Davis, California, United States of America.
University of California, Davis · USUniversity of California, San Francisco · USBouygues (France) · FRFreie Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary stone disease, particularly calcium oxalate, is common in both humans and cats. Calcifying nanoparticles (CNP) are spherical nanocrystallite material, and are composed of proteins (fetuin, albumin) and inorganic minerals. CNP are suggested to play a role in a wide array of pathologic mineralization syndromes including urolithiasis. We documented the development of a clinically relevant protocol to assess urinary CNP in 9 healthy cats consuming the same diet in a controlled environment using Nanoparticle Tracking Analysis (NTA®). NTA® is a novel method that allows for characterization of the CNP in an efficient, accurate method that can differentiate these particles from other urinary submicron particulates. The predominant nanoscale particles in feline urine are characteristic of CNP in terms of their size, their ability to spontaneously form under suitable conditions, and the presence of an outer layer that is rich in calcium and capable of binding to hydroxyapatite binders such as alendronate and osteopontin. The expansion of this particle population can be suppressed by the addition of citrate to urine samples. Further, compounds targeting exosomal surfaces do not label these particulates. As CNP have been associated with a number of significant urologic maladies, the method described herein may prove to be a useful adjunct in evaluating lithogenesis risk in mammals.

Indexed as

AlendronateAnimalsCalcifying NanoparticlesCatsCitric AcidDurapatiteFemaleFluorescent DyesMaleMicroscopy, Electron, TransmissionOsteopontinParticle SizeUrolithiasisAlendronateCalcifying NanoparticlesCitric AcidDurapatiteFluorescent DyesOsteopontin

Identifiers

PMID28005930
PMCPMC5179072
OpenAlexW2566360110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.